Residency · Residency · Neurology

Disease-Modifying Therapy for Multiple Sclerosis

Overview

Over 20 FDA-approved disease-modifying therapies (DMTs) are available for relapsing forms of MS, and the treatment landscape has shifted dramatically from injectable platform therapies to high-efficacy agents. The central debate in MS treatment revolves around the escalation approach (starting with a lower-efficacy, safer therapy and escalating for breakthrough disease) versus early high-efficacy therapy (EHT). The goal of treatment is to reduce relapse rate, delay disability progression, and minimize new MRI lesion activity. The aspirational outcome measure is "no evidence of disease activity" (NEDA-3), defined as no relapses, no disability progression, and no new or enlarging MRI lesions.

The Escalation vs. Early High-Efficacy Debate

Escalation Approach

The escalation strategy begins with a moderately effective, safer therapy such as interferon, glatiramer acetate, or dimethyl fumarate, and escalates to higher-efficacy therapy if breakthrough disease occurs. The advantage is avoiding exposure of low-risk patients to immunosuppressive risks. The disadvantage is that subclinical disease activity may cause irreversible axonal damage before escalation is triggered.

Early High-Efficacy Therapy (EHT)

The EHT approach starts with a high-efficacy agent (natalizumab, ocrelizumab, alemtuzumab, or ofatumumab) from the time of diagnosis. Growing evidence supports better long-term outcomes with EHT, particularly in patients with poor prognostic features. The DELIVER-MS and TREAT-MS trials are studying EHT versus escalation head-to-head. Observational data from MSBase and Big MS Data registries consistently show better disability outcomes with early high-efficacy treatment. The risk is exposing patients who might have had benign disease to unnecessary immunosuppressive side effects.

Patient Selection for EHT

Features favoring early high-efficacy treatment include high lesion burden at diagnosis (9 or more T2 lesions), spinal cord lesions, gadolinium-enhancing lesions at baseline, incomplete recovery from the initial attack, high relapse rate early in disease, young age (providing more time to accrue disability), and poor prognostic biomarkers such as neurofilament light chain elevation and brain atrophy.

Platform (Injectable) Therapies

Interferon-Beta (IFN-beta)

Available agents include IFN-beta-1a (Avonex administered intramuscularly weekly, Rebif administered subcutaneously three times per week), IFN-beta-1b (Betaseron/Extavia administered subcutaneously every other day), and peginterferon-beta-1a (Plegridy administered subcutaneously every 2 weeks). These provide approximately 30% relapse reduction through anti-inflammatory and immunomodulatory mechanisms that reduce T-cell migration across the blood-brain barrier. Side effects include flu-like symptoms (injection-site reactions, myalgias, fever), liver enzyme elevation, leukopenia, and possibly depression (debated). Neutralizing antibodies can develop and reduce efficacy. Monitoring requires CBC and LFTs every 3-6 months and thyroid function testing.

Glatiramer Acetate (Copaxone, Glatopa)

Glatiramer acetate is a synthetic copolymer of amino acids that mimics myelin basic protein, administered as 20 mg daily or 40 mg three times per week subcutaneously. It provides approximately 30% relapse reduction and is well tolerated. Side effects include injection-site reactions, a rare self-limited post-injection reaction (chest tightness, flushing), and lipoatrophy at injection sites. No laboratory monitoring is required. It is considered safe in pregnancy and is often continued until conception.

Oral Therapies

Dimethyl Fumarate (Tecfidera) / Diroximel Fumarate (Vumerity) / Monomethyl Fumarate (Bafiertam)

These agents activate the Nrf2 pathway (antioxidant) and have immunomodulatory properties. They provide approximately 50% relapse reduction as demonstrated in the DEFINE and CONFIRM trials. Side effects include GI symptoms (nausea, diarrhea, abdominal pain that often improve over weeks), flushing, and lymphopenia. There is a risk of PML in patients with prolonged lymphopenia (below 500 per microliter for more than 6 months), necessitating CBC monitoring every 6 months. Diroximel fumarate has improved GI tolerability.

Fingolimod (Gilenya)

Fingolimod was the first oral DMT approved for MS. It is a sphingosine-1-phosphate (S1P) receptor modulator that traps lymphocytes in lymph nodes, providing approximately 54% relapse reduction (FREEDOMS, TRANSFORMS trials). Side effects include first-dose bradycardia (requiring 6-hour cardiac monitoring at initiation), macular edema (ophthalmologic exam at 3-4 months), increased infections, herpes zoster (VZV titer and vaccination required before starting), lymphopenia, and elevated liver enzymes. A significant concern is the rebound effect, with disease reactivation upon discontinuation that can be severe. PML risk is rare (approximately 1 in 12,000 patient-years). Newer S1P receptor modulators include siponimod (Mayzent, also approved for SPMS), ozanimod (Zeposia), and ponesimod (Ponvory), which are more selective for S1P1/S1P5 receptors with faster onset and offset, and some do not require first-dose monitoring.

Teriflunomide (Aubagio)

Teriflunomide inhibits dihydroorotate dehydrogenase, reducing pyrimidine synthesis in rapidly dividing lymphocytes. It provides approximately 30-36% relapse reduction (TEMSO, TOWER trials). Side effects include alopecia, GI symptoms, hepatotoxicity, and rare peripheral neuropathy. It is teratogenic (FDA Pregnancy Category X) and requires an accelerated elimination procedure (cholestyramine or activated charcoal) before conception with drug level monitoring. Laboratory monitoring includes LFTs monthly for 6 months then periodically, blood pressure, and CBC.

Cladribine (Mavenclad)

Cladribine is a purine nucleoside analogue that selectively depletes lymphocytes (CD4 and CD8 T cells, B cells). It is given as a short oral course: 10 days of treatment in year 1 repeated in year 2, with no treatment in years 3 and 4. It provides approximately 58% relapse reduction (CLARITY trial). As a reconstitution immunotherapy, its effects persist beyond the treatment period. Side effects include lymphopenia, herpes zoster, and a theoretical malignancy risk (not confirmed in long-term data). It is contraindicated in pregnancy and requires effective contraception.

<image>Comparison chart of MS disease-modifying therapies showing mechanism of action, route of administration, approximate relapse reduction, and key safety considerations for each class</image>

Infusion Therapies

Natalizumab (Tysabri)

Natalizumab is an anti-alpha4-integrin monoclonal antibody that blocks lymphocyte migration across the blood-brain barrier, providing approximately 68% relapse reduction (AFFIRM trial) and making it one of the most effective therapies. It is administered as a monthly IV infusion, with a subcutaneous formulation also available. The key risk is progressive multifocal leukoencephalopathy (PML). JC virus (JCV) antibody index stratification guides risk assessment: negative status confers very low risk (approximately 0.1 per 1000), positive with index 0.9 or below is low risk, and positive with index above 1.5 is high risk (approximately 1 in 100 at 2 years of treatment). Risk increases with JCV antibody positivity, longer treatment duration (especially beyond 2 years), and prior immunosuppression. Extended interval dosing (every 6-8 weeks instead of 4 weeks) may reduce PML risk while maintaining efficacy (NOVA study). Monitoring includes JCV antibody status every 6 months, brain MRI every 3-6 months (more frequently if JCV positive), CBC, and LFTs.

Ocrelizumab (Ocrevus)

Ocrelizumab is an anti-CD20 monoclonal antibody that depletes CD20-positive B cells, providing approximately 46% relapse reduction in RRMS (OPERA I/II trials). It is the first DMT to demonstrate efficacy in PPMS, with a 24% reduction in 12-week confirmed disability progression (ORATORIO trial). It is administered as an IV infusion every 6 months after initial loading doses. Side effects include infusion reactions (mitigated by premedication), infections (especially upper respiratory), herpes zoster, a possible increased risk of breast cancer (a signal in trials not confirmed subsequently), and hypogammaglobulinemia with prolonged use. Monitoring includes CBC, immunoglobulin levels periodically, hepatitis B screening before initiation, and age-appropriate cancer screening.

Ofatumumab (Kesimpta)

Ofatumumab is a fully human anti-CD20 monoclonal antibody administered as a monthly subcutaneous self-injection after loading doses, providing approximately 51% relapse reduction (ASCLEPIOS I/II trials). It offers the convenience of self-administration versus infusion center visits, with a safety profile similar to ocrelizumab.

Alemtuzumab (Lemtrada)

Alemtuzumab is an anti-CD52 monoclonal antibody that causes profound lymphocyte depletion followed by immune reconstitution. It provides approximately 55% relapse reduction versus IFN-beta-1a (CARE-MS I/II trials). It is administered as IV infusions over 5 consecutive days in year 1 and 3 consecutive days in year 2, with additional courses as needed. Significant safety concerns include secondary autoimmunity (thyroid disease in approximately 40%, ITP in approximately 2%, anti-GBM nephritis in approximately 0.3%), infections, infusion reactions, and rare stroke risk. A REMS program is required. It is generally reserved for highly active disease refractory to other therapies.

Ublituximab (Briumvi)

Ublituximab is an anti-CD20 monoclonal antibody with a glycoengineered Fc for enhanced antibody-dependent cellular cytotoxicity, administered as a 1-hour IV infusion every 6 months. It provides approximately 60% relapse reduction (ULTIMATE I/II trials) and offers a shorter infusion time compared to ocrelizumab.

JCV Risk Stratification and PML

JCV antibody testing with index value should be performed before and during natalizumab therapy. PML risk is negligible with JCV antibody negative status (test every 6 months for seroconversion). If the patient is JCV positive with an index above 1.5 and has been treated for more than 18 months, switching to an alternative therapy should be discussed. PML surveillance MRI should be performed every 3-4 months for JCV-positive patients on natalizumab. PML presents with subacute cognitive, motor, or visual decline, with MRI showing progressive non-enhancing white matter lesions distinct from MS lesions. Treatment of PML involves stopping natalizumab, performing plasmapheresis to remove the drug, and providing supportive care; immune reconstitution inflammatory syndrome (IRIS) may occur during recovery.

<image>JCV stratification algorithm for natalizumab showing risk categories based on antibody index, treatment duration, and prior immunosuppression, with corresponding management recommendations</image>

Treatment of Progressive MS

Secondary Progressive MS (SPMS)

Siponimod (Mayzent) is FDA-approved for SPMS with active disease based on the EXPAND trial. Cladribine, ocrelizumab, and natalizumab may benefit SPMS patients with ongoing inflammatory activity. If the disease is purely progressive without relapses or new MRI lesions, DMT benefit is limited.

Primary Progressive MS (PPMS)

Ocrelizumab is the only FDA-approved DMT for PPMS (ORATORIO trial), with benefit most pronounced in younger patients with gadolinium-enhancing lesions. Symptomatic management of spasticity, bladder dysfunction, fatigue, and pain is equally important.

Treatment Sequencing and Switching

Washout periods vary by mechanism: short for interferons and glatiramer acetate, longer for fingolimod (rebound risk), teriflunomide (requires accelerated elimination), and natalizumab (PML risk during washout). When switching from natalizumab, a quick bridge to the next therapy (within 4-8 weeks) is essential to avoid rebound, with fingolimod or anti-CD20 therapies being common switch targets. Lymphocyte counts should be monitored before starting new therapy after lymphocyte-depleting agents. For anti-CD20 therapies, immunoglobulin levels (especially IgG and IgM) should be checked before retreatment, as hypogammaglobulinemia may necessitate dose extension or supplemental immunoglobulin.

Clinical Pearls

The "time is brain" principle applies in MS: every relapse and every new lesion represents irreversible axonal loss, making early, effective treatment critical. NEDA (no evidence of disease activity) is the aspirational treatment goal, with NEDA-4 adding brain volume loss as a fourth metric. JCV antibody status must always be checked before starting natalizumab and repeated every 6 months because seroconversion changes the risk calculus. Fingolimod discontinuation can cause severe rebound relapses sometimes worse than pre-treatment disease activity, so a rapid bridge to the next DMT must be planned. Vaccinations, especially live vaccines, should be administered before starting immunosuppressive DMTs; live vaccines are contraindicated during anti-CD20 therapy because the immune response to vaccines is blunted. VZV serologies and vaccination should be completed before starting fingolimod, siponimod, or cladribine. Pregnancy planning is essential: teratogenic agents (teriflunomide, fingolimod, cladribine) must be stopped well in advance, glatiramer acetate and natalizumab are sometimes continued until conception, and anti-CD20 agents are typically held 6-12 months before planned pregnancy. MS disease activity is highest in the postpartum period, so DMT resumption should be planned promptly after delivery with consideration of breastfeeding compatibility.

References

• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I and OPERA II). N Engl J Med. 2017;376(3):221-234.
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO). N Engl J Med. 2017;376(3):209-220.
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis (AFFIRM). N Engl J Med. 2006;354(9):899-910.
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788.
• He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316.

Read this lecture as Markdown